5 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital

4. TG Therapeutics, Inc. (NASDAQ:TGTX)

Maverick Capital’s Stake Value: $109 million

Percentage of Maverick Capital’s 13F Portfolio: 1.11%

Number of Hedge Fund Holders: 23

TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company whose products cover several types of leukemias and autoimmune diseases.

Maverick Capital owned a $109 million stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during 2021’s third quarter. This was through holding 3.2 million shares and it represented 1.11% of the firm’s portfolio. An Insider Monkey survey of 867 hedge funds for the same time period revealed that 23 funds owned the company’s shares.

For its fiscal Q3, TG Therapeutics, Inc. (NASDAQ:TGTX) sorely disappointed analysts as it missed estimates for revenue by a mile and failed to meet them for GAAP EPS as well. The company’s $2 million revenue for the quarter missed estimates by $0.94 million. In December 2021, Evercore ISI reduced the company’s price target to $36 from $55, citing worries about a potential Food and Drug Administration (FDA) advisory committee concerns for the company’s drug.

Peter Kolchinsky’s RA Capital Management is TG Therapeutics, Inc. (NASDAQ:TGTX)’s largest investor. It has a $136 million stake in the company through 4 million shares.